San Diego-dependent Viking Therapeutics marked alone as a significant competitor while in the weight loss drug industry in February after revealing promising facts from the mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the company